Vice President - Technical Operations
Jason Burdette has over 25 years experience in the pharmaceutical industry concentrated on formulation and process development, manufacturing, supply chain management and technical operations. He brings extensive experience in new product introduction of multiple products in both the US and international markets. Mr. Burdette joins us from Eagle Pharmaceuticals where he was the VP, Supply Chain. At Eagle he was responsible for supply chain management, procurement, distribution and new product introduction. Mr. Burdette joined Eagle from Shire Pharmaceuticals where he held various positions with increasing responsibility over his 10-year tenure. Including, VP Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, Global Product Director, Supply Chain for the ADHD business. He was an active member of the supply chain leadership team and the international commercial team among other key executive leadership teams. Prior to Shire Pharmaceuticals, Mr. Burdette worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals.
Senior Vice President - Business Development
Jeanne Jew joined Pino in July 2015. Ms. Jew has more than 20 years of experience in business development, product planning and general management in the biotechnology industry. Prior to joining Pino, Ms. Jew was Senior Vice President, Business Development of KaloBios Pharmaceutical where she was responsible for business development, strategic planning, and marketing. During her tenure at KaloBios, Ms. Jew was responsible for the execution and management of its partnership with Sanofi Pasteur, and played in key role in the IPO. From 2002-2007, Ms. Jew served as Vice President of Corporate Development of Onyx Pharmaceuticals, where she was responsible for all business development activities and commercial planning for Nexavar. Prior to Onyx Pharmaceuticals, Ms. Jew held business development positions at Coulter Pharmaceuticals and became Vice President, Business Development following the acquisition of Coulter Pharmaceutical by Corixa Corporation. Earlier in her career, Ms. Jew held business development positions at Scios, Inc. and Genentech, Inc. Ms. Jew holds a Bachelor of Arts in psychology from Wesleyan University and a Master of Business Administration from Cornell University.
Paul McGovern, M.D.
Vice President - Clinical and Medical Affairs
Paul McGovern, M.D. joined Pino in February 2017 as a Vice President of Clinical and Medical Affairs. Prior to joining Pino, Dr. McGovern worked in Global Clinical Development at Actelion Clinical Research as a Clinical Science Program Head for cadazolid, an antibiotic in late development for Clostridium difficile infection and as an Infectious Diseases expert for other anti-infective products in development. From 2006-2013, Dr. McGovern held positions in Medical and Clinical Affairs at Wyeth and Pfizer where he worked on the tigecycline late life-cycle strategy and activities including the benefit risk. Dr. McGovern has a B.S. from the University of Notre Dame and a M.D. from Northwestern University. He completed an Internal Medicine Residency and Infectious Diseases Fellowship at the University of Pennsylvania. Following the completion of his medical training, Dr. McGovern was a faculty member at the University of Pennsylvania prior to joining Wyeth in 2006.
Vice President - Information Technology
Raj Padmanabhan is our Vice President, Information Technology (IT), facilities and space planning and has served in this position since November, 2015. With more than 20 years of experience, Mr. Padmanabhan previously served as Senior Director, IT Architecture, Quality and Processes at Cubist Pharmaceuticals, a wholly owned subsidiary of Merck. During his eight-year tenure at Cubist, Mr. Padmanabhan built Information Technology infrastructure to scale business operations and support the growth of the business including successful launch of two new anti-infective products in US and international markets and successful relaunch of two commercial products in US market. Mr. Padmanabhan led several leadership task forces to increase productivity and ensure compliance with federal regulations. Prior to Cubist, Mr. Padmanabhan was Associate Director, Business and Integration Service at Biogen where he implemented global systems to support compliance with federal regulations, improve productivity and reduce costs. Raj Padmanabhan has a Bachelor of Engineering degree in Computer science and Engineering from University of Madras and a Masters in Business Administration from Babson College.
Susan Perkins J.D.
Vice President - Intellectual Property
Susan Perkins, J.D., prior to joining Pino, Ms. Perkins has been sole in-house patent counsel for multiple start-up biotechnology companies, managing portfolios for clinical stage and preclinical drug candidates while building platform technology IP. Most recently, Ms. Perkins was Head of Intellectual Property at Aileron Therapeutics, a leader in Stapled Peptide therapeutics. Prior to that she led IP at Avila Therapeutics (acquired by Celgene), Syntonix Pharmaceuticals (acquired by Biogen Idec) and Leukosite (acquired by Millennium Pharmaceuticals for which Ms. Perkins continued as patent counsel). Before going in-house, Ms. Perkins was associated with the law firm of Campbell & Flores in San Diego, CA. She began as a Patent Examiner with the U.S. Patent & Trademark Office. She holds a J.D. with Honors from the George Washington University, which included an externship with the Honorable Randall Radar of the U.S. Court of Appeals for the Federal Circuit. Ms. Perkins holds an advanced degree in chemistry from the University of North Carolina, and graduated Summa Cum Laude from UMass-Amherst.